Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation

Jian Gu,Xiaozhang Xu,Xiangyu Li,Lei Yue,Xiaowen Zhu,Qiuyang Chen,Ji Gao,Maruyama Takashi,Wenhu Zhao,Bo Zhao,Yue Zhang,Minjie Lin,Jinren Zhou,Yuan Liang,Shipeng Dai,Yufeng Pan,Qing Shao,Yu Li,Yiming Wang,Zibo Xu,Qufei Qian,Tianning Huang,Xiaofeng Qian,Ling Lu

DOI: https://doi.org/10.1038/s41388-024-03080-7

IF: 8.756

2024-06-20

Oncogene

Abstract:The role of tumor-resident microbiota in modulating tumor immunity remains unclear. Here, we discovered an abundance of intra-tumoral bacteria, such us E.coli , residing and resulting in Colorectal cancer liver metastasis (CRLM). E.coli enhanced lactate production, which mediated M2 macrophage polarization by suppressing nuclear factor-κB -gene binding (NF-κB) signaling through retinoic acid-inducible gene 1 (RIG-I) lactylation. Lactylation of RIG-I suppressed recruitment of NF-κB to the Nlrp3 promoter in macrophages, thereby reducing its transcription. This loss of Nlrp3 affected the immunosuppressive activities of regulatory T cells (Tregs) and the antitumor activities of and CD8 + T cells. Small-molecule compound screening identified a RIG-I lactylation inhibitor that suppressed M2 polarization and sensitized CRLM to 5-fluorouracil (5-FU). Our findings suggest that tumor-resident microbiota may be a potential target for preventing and treating CRLM.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The paper primarily explores the role of tumor-resident microbiota in regulating tumor immunity and discovers how these microbiota, particularly Escherichia coli (E. coli), promote the process of colorectal cancer liver metastasis (CRLM).

Specifically, the study finds that a large number of bacteria, such as E. coli, exist within tumors and promote the development of CRLM by increasing lactate production. The increase in lactate leads to the polarization of M2 macrophages, which is achieved by inhibiting the NF-κB signaling pathway. The specific mechanism involves lactate-induced lactylation of the RIG-I protein. Lactate reduces the aggregation of MAVS protein and the activation of NF-κB by lactylating the lysine residue at position 852 of RIG-I (RIG-IK852), thereby decreasing the expression of the NLRP3 gene. This further affects the function of regulatory T cells (Tregs) and the antitumor activity of CD8+ T cells.

The main contributions of the paper include:
1. Revealing the association between intratumoral microbiota and CRLM, with significant differences in microbial abundance observed in samples from Chinese patients.
2. Identifying that E. coli can promote the development of CRLM by increasing lactate levels.
3. Elucidating that lactate inhibits the NF-κB signaling pathway by lactylating RIG-IK852, thereby reducing the transcription of NLRP3, affecting macrophage polarization and T cell function.
4. Proposing RIG-I lactylation inhibitors as potential therapeutic agents that can inhibit M2 macrophage polarization and enhance sensitivity to the chemotherapeutic drug 5-fluorouracil (5-FU).

In summary, this study provides new insights into how tumor-resident microbiota promote cancer metastasis through immune regulatory mechanisms and lays the foundation for developing novel antimicrobial-based therapies to prevent and treat CRLM.